Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	69.41T -2.1%
Revenue (ttm)	5.12T +50.3%
Net Income	1.98T +54.3%
EPS	45,556.40 +64.0%
Shares Out	46.24M
PE Ratio	35.35
Forward PE	33.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,227
Open	1,501,000
Previous Close	1,501,000
Day's Range	1,451,000 - 1,505,000
52-Week Range	1,228,000 - 1,987,000
Beta	0.21
Analysts	Strong Buy
Price Target	1,975,520.00 (+33.75%)
Earnings Date	Oct 21, 2026

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,047
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2025, Samsung Biologics's revenue was 4.56 trillion, an increase of 30.31% compared to the previous year's 3.50 trillion. Earnings were 1.78 trillion, an increase of 64.71%.

Analyst Summary

According to 25 analysts, the average rating for 207940 stock is "Strong Buy." The 12-month stock price target is ₩1,975,520, which is an increase of 33.75% from the latest price.

Price Target

₩1,975,520

(33.75% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 3, 2026

Data Sources Report a data error